Reclaiming Asia’s Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Address: 18th Floor, Hanjin Main Bld, 118, Namdaemunno-2-ga, Seoul,Republic of Korea
Tel: +82 2 772 4000
With more than thirty years of experience as one of Republic of Korea’s premiere full-service law firms, Lee & Ko has a widely recognized and long-established record of excellence in providing expert legal advice and representation to its diverse clientele in domestic and international matters involving all areas of legal practice. ith a wealth of experience in virtually all aspects of corporate law practice, Lee & Ko continues to be a highly regarded leader among Republic of Korean law firms in providing excellent legal services and creative approaches to both domestic and foreign clients doing business in or with Republic of Korea. With some of Republic of Korea’s most experienced and capable corporate law practitioners among its partners and associates, Lee & Ko’s clients receive the highest quality, the most efficient, and the most innovative legal assistance available. Lee & Ko has a distinguished and well-deserved reputation for consistently providing timely, up-to-date, accurate and reliable legal assistance with all manner of corporate legal matters, including incorporation and registration, corporate governance issues and the issuance of corporate securities.
In addition, Lee & Ko has one of Republic of Korea’s most capable, versatile and extensive legal practices in domestic and cross-border mergers and acquisitions. Lee & Ko has served as key legal counsel for innumerable foreign and domestic clients in connection with a broad range of highly complex and sensitive transactions, particularly in recent decades as the Republic of Korean corporate landscape has become more international and complex.
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
See our Cookie Privacy Policy Here
